Keywords: Vifor Pharma, Ferinject, Anemia, Iron deficiency, Cancer patients

Observational study suggests a role for Vifor's Ferinject for anemic and iron deficient patients with cancer

Article | 31 January 2013

Print This

Swiss firm Vifor Pharma, a subsidiary of the Galenica Group (GALN: SIX), notes the publication of an observational study in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in